Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
  • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
  • Contact Us
  • Menu Menu
You are here: Home1 / About Us

Our Vision

To improve global human health by providing broad and robust, long-term immunity for some of the world’s most pressing infectious diseases.

Understand our approach in under 4 minutes

Emergex, a clinical-stage, privately held biotechnology company headquartered in Oxfordshire, Abingdon, UK, with R&D facilities in Milton Park, UK, an operating subsidiary in Doylestown, Pennsylvania, and GMP manufacturing facility in Fremont, CA, USA. Emergex is pioneering the development a range of 100% synthetic CD8+ T cell-priming immune set-point candidates designed to harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide broad and robust immune protection for some of the world’s most urgent infectious diseases.

Our Technology Our Advantages

Emergex’s T cell-priming immune set-point candidates combine two proprietary technologies

  • To offer broad and robust, cross-reactive protection against viruses of the same family, as well as against existing and potential variants (one product, multiple pathogen protection)
  • To extend duration of immune protection, potentially for up to decades
  • To enable transport and storage for extended periods of time with stability at room temperature (avoiding conventional cold chain requirements)
  • To be delivered via intradermal micro-needles directly into the skin, avoiding conventional needle administration
  • To be suited for rapid ‘plug and play’ development and scale-up with an ultrasmall passivated nanocluster delivery platform.
  • Activation of T-cell by activated dendritic cell.

  • Infected cell death by T cell.

  • Dendritic cell activation.

PreviousNext
123

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top